Table 2.
CXB use associated with early prevention of oral cancer (Group 1) occurrence in a retrospective cohort study.
| Characteristic | Without CXB use | With CXB use | p value |
|---|---|---|---|
| n (%) | n (%) | ||
| Total subjects | 554965 | 49209 | |
| Gender | |||
| Male | 275117 (49.57) | 18067 (36.71) | <0.0001 |
| Female | 279848 (50.43) | 31142 (63.29) | |
| Age (years) | |||
| 18–39 | 356630 (64.26) | 5864 (11.92) | <0.0001 |
| 40–59 | 163516 (29.46) | 22661 (46.05) | |
| ≥60 | 34819 (6.27) | 20684 (42.03) | |
| Oral cancer | |||
| No | 553256 (99.69) | 49094 (99.77) | 0.0004 |
| Yes | 1709 (0.31) | 115 (0.23) | |
| ICD-9-CM | |||
| 140 | 139 (8.13) | 7 (6.09) | |
| 141 | 493 (28.85) | 40 (34.78) | |
| 143 | 107 (6.26) | 5 (4.35) | |
| 144 | 43 (2.52) | 1 (0.87) | |
| 145 | 927 (54.24) | 62 (53.91) | |
| Preventive effect based on prescription record of CXB use† | 1.00 | 0.51 (0.42–0.62)* | |
| Dose-dependent effect | |||
| Dose (100 mg daily) | 1.00 | 1.01 (0.77–1.34) | |
| Dose (100/200 mg daily) | 1.00 | 0.55 (0.37–0.81)* | |
| Dose (200 mg daily) | 1.00 | 0.28 (0.20–0.40)* | |
| Ptrend < 0.0001 | |||
| Time-dependent effect‡ | |||
| 1–3 years | 1.00 | 0.84 (0.66–1.07) | |
| 3–5 years | 1.00 | 0.65 (0.38–1.13) | |
| ≥5 years | 1.00 | 0.33 (0.22–0.48)* | |
| Ptrend < 0.0001 | |||
†Hazard ratio was examined using a Cox proportional hazard model with adjustment for the age and gender in a cohort study followed up from 1997 to 2010.
‡Follow-up years after the first CXB use.
*p < 0.01.